Use of the Nuclear Matrix Protein 22 BladderChek Test for the Detection of Primary and Recurrent Urothelial Carcinoma
Table 2
Distributions of primary and recurrent urothelial carcinoma by site, stage, and grade.
Site/stage/grade
Primary
Number (%)
Primary # Number (%)
Recurrent
Number (%)
Site
Bladder
68 (66.0%)
22 (45.8%)
29 (100.0%)
Ureter
15 (14.6%)
11 (22.9%)
0 (0.0%)
Renal pelvis
12 (11.6%)
9 (18.8%)
0 (0.0%)
Renal collecting duct
1 (1.0%)
1 (2.1%)
0 (0.0%)
Bladder and renal pelvis
2 (1.9%)
1 (2.1%)
0 (0.0%)
Bladder, ureter, and renal pelvis
1 (1.0%)
0 (0.0%)
0 (0.0%)
Ureter and renal pelvis
4 (3.9%)
4 (8.3%)
0 (0.0%)
Stage
Ta
34 (33.0%)
8 (16.7%)
7 (24.1%)
T1
31 (30.1%)
15 (31.2%)
12 (41.4%)
T2
28 (27.2%)
20 (41.7%)
6 (20.7%)
T3+T4
10 (9.7%)
5 (10.4%)
4 (13.8%)
Grade
PNLMP
9 (8.7%)
0 (0.0%)
0 (0.0%)
Low
29 (28.2%)
11 (22.9%)
5 (17.2%)
High
65 (63.1%)
37 (77.1%)
24 (82.8%)
Note: patients performed the NMP22 BladderChek tests; #patients performed the NMP22 BladderChek tests and urine cytology tests; PNLMP: papillary neoplasm of low malignant potential.
